The Administrative Court of Piedmont, with judgment no. 979 of 30th September 2024, formulated an important clarification on public tenders for the purchase of medicinal products, according to which the ban, provided for by art. 15, paragraph 11 quater, of the law decree no. 95/2012, to create single batches in competition between biological and biosimilar medicinal products having different active ingredients also applies in the event that Aifa has stated the therapeutic equivalence among the originator products pursuant to art. 15, paragraph 11 ter, of the law decree no. 95/2012. This means that, given the peculiarities and intrinsic variability that characterize this type of medicinal product, the opinion of therapeutic equivalence between the original product A and the original product B does not automatically extend to the respective biosimilar products.